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Abstract
The issue of small coronary artery atherosclerosis represents an intriguing aspect of coronary artery dis-
ease, which is related with higher rates of peri- and post-procedural complications and impaired long-
-term outcome. This problem is further complicated by the unclear definition of small coronary vessel. 
Recent randomized controlled trials have provided new data on possible novel interventional treatment 
of small coronary vessels with drug-coated balloons instead of traditional new-generation drug-eluting 
stent implantation. Also, the conservative management represents a therapeutic option in light of the 
results of the recent ISCHEMIA trial. The current article provides an overview of the most appropriate 
definition, interventional management, and prognosis of small coronary artery atherosclerosis. (Cardiol 
J 2021; 28, 5: 767–778)
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Introduction
The first successful percutaneous coronary in-
tervention (PCI) was performed in 1977. Since this 
time interventional cardiology has made huge pro-
gress owing to rapid improvement of technology. 
However, treatment of stenoses in small coronary 
arteries remains an uncharted clinical territory in 
terms of decision-making and optimal technique 
of intervention. Depending on the applied defini-
tion, the prevalence of small vessel disease (SVD) 
reaches roughly 1/3 of patients with symptomatic 
coronary artery disease (CAD) [1, 2], especially 
patients with chronic kidney disease (CKD) [3], 
diabetes mellitus [4], and active smokers [5–7]. 
The clinical significance of small vessel athero-
sclerosis is related to its frequently diffuse nature 
[8, 9]. Although some patients may present with 
isolated one-vessel significant stenosis in a small 
coronary artery (Fig. 1), a considerable group of pa-
tients have diffuse atherosclerosis not amenable to 
endovascular and surgical revascularization (Fig. 2). 
In this clinical scenario, only optimal medical 
therapy represents a therapeutic option, and SVD 
should be regarded as an end-stage phase of CAD 
[10]. Also, it is important to distinguish SVD from 
coronary microvascular spasm, which represents 
a different clinical entity not amenable to percuta-
neous intervention but tailored for a pharmacologi-
cal approach [11].
This article, however, primarily discusses 
clinical scenarios, in which revascularization is 
a therapeutic option, alongside the best medical 
therapy (Fig. 1). In this case, one should take 
into consideration the possible clinical benefits 
and complications of PCI performed in such clini-
cal circumstance. On the one hand, even a small 
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impaired quality of life, and malignant ventricular 
arrhythmias [12]. On the other hand, an attempt 
of PCI may expose patients to the risk of coronary 
artery perforation, cardiac tamponade, and peri-
procedural myocardial infarction (MI) [13, 14]. 
However, the most important limitation of PCI in 
SVD is related with a higher rate of hemodynami-
cally significant restenosis [15], which is primarily 
conditioned by lower initial lumen gain, rather than 
greater lumen loss as compared to PCI within ves-
sels with larger diameter [2].  A large body of evi-
dence suggests that smaller stent diameter suitable 
for SVD also constitutes a strong predictor of acute 
stent thrombosis (ST) [16]. Small stent diameter, 
along with increased total stent length and larger 
strut thickness, constitute powerful periprocedural 
predictors of long-term outcome [17].
The clinical profile of SVD patients, as well 
as higher rate of short- and long-term procedural 
complications, translates into poor long-term out-
comes [3, 5]. Despite the use of new-generation 
drug-eluting stents (DES), an accumulating body 
of evidence suggests that PCI of coronary arter-
ies < 2.5 mm is associated with a high rate of 
target lesion failure (TLF) or cardiovascular death 
[5]. Given the clinical significance of SVD, in the 
present article we will attempt to summarize the 
current knowledge on the definition, different 
approaches to interventional management, and 
outcomes of small coronary artery atherosclerosis.
Figure 1. Example of small vessel disease amenable to percutaneous coronary intervention (RAO 30o; CRAo). A. Acute 
occlusion of small (1.5 mm) diagonal branch (arrow); B. Final angiographic result; percutaneous coronary intervention 
with 2.0 × 18 mm everolimus-eluting stent implantation in the proximal part of the vessel with slight oversize (left ar-
row); the image shows considerable length and extensive area supplied by the initially occluded vessel (right arrow).
Figure 2. Example of diffuse small coronary artery ath-
erosclerosis suitable for medical management (LAO 
15o, CRA 30o); widespread significant lesions located 
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Methods
This paper was based on systematic assess-
ment of randomized controlled trials, observational 
and cohort studies, and meta-analyses comparing 
different strategies for the treatment of coronary 
stenoses located exclusively in small diameter ves-
sels. The PubMed, EMBASE, Cochrane Library, 
and Clinical trial registries databases were searched 
using a combination of relevant text terms and key 
words: small coronary artery disease, small ves-
sel coronary artery disease, small vessel disease, 
percutaneous coronary intervention, small coro-
nary vessels, small coronary arteries, treatment, 
revascularization strategies, drug-coated balloons, 
drug-eluting stents, clinical trial, randomized trial, 
and meta-analysis. No language or sample size re-
strictions were applied. The review covered studies 
published between 1978 and April 2020.
Definition and characteristics
The greatest limitation of research in the field 
of SVD is the unclear definition of small coronary 
vessels used in the literature, which has evolved 
over the years. On the other hand, on closer ex-
amination, the small vessel diameter may be mis-
leading and may derive from high plaque burden 
and diffuse disease. 
Based on the meta-analysis by Agostoni et al. 
[18], SVD was liberally defined as atherosclerosis 
within the artery < 3.0 mm. Also, the recent 
BASKET-SMALL 2 trial arbitrarily adopted the 
diameter threshold of < 3.0 mm as SVD [19]. Early 
trials progressively identified vessels ≤ 2.9 mm or 
≤ 2.75 mm in diameter as SVD [20, 21]. It is vital 
to note that these studies used these cut-off val-
ues as inclusion criteria, which were not validated 
against comparator cut-off values. A sub-study of 
the DUTCH-PEERS trial showed that a diameter 
of 2.5 mm appropriately stratifies patients in terms 
of risk of TLF [5]. Coronary arteries with diameter 
2.5–3.0 were characterized by low risk of long-term 
complications as compared to vessels > 3.0 mm. 
Conversely, the risk was far greater in vessels 
< 2.5 mm [5]. In the IRIS-DES registry, everolimus- 
-eluting stent < 2.78 mm and biolimus-eluting 
stent < 3.20 mm corresponded with increased 
risk of composite endpoint of cardiac death, target-
vessel MI, and revascularization [17]. Very small 
vessel CAD was defined by Biondi-Zoccai et al. [7]; 
the definition considers vessels amenable to inter-
vention using a 2.25 mm balloon or stent.
One should take into consideration the fact 
that the impact of vessel diameter on prognosis, 
including the risk of in-stent restenosis (ISR) or 
ST, is not categorical, and it should be regarded as 
a continuous variable (Fig. 3). 
Diagnostic work-up and indication  
for myocardial revascularization
The decision-making process in patients with 
SVD should in general follow the same rules 
as described in European Society of Cardiology 
Guidelines for Myocardial Revascularization [22]. 
Depending on the clinical scenario, patients with 
acute coronary syndrome (ACS) should proceed to 
emergent invasive coronary angiography in cases of 
ST-segment elevation MI or non-ST-segment ACS 
with signs of hemodynamic or electrical instability 
or refractory angina. According to the guidelines 
on the management of chronic coronary syndromes 
(CCS), prior to invasive coronary angiography, all 
patients should be adequately verified in terms 
of the presence of ischemia using a non-invasive 
stress test [23].
Functional assessment
Prior to decision of myocardial revasculariza-
tion, regardless of the vessel size, hemodynamic 
significance should be verified using fractional flow 
reserve (FFR) or instantaneous wave-free ratio 
measurements [24]. The PHANTOM trial provided 
evidence that purely angiographic assessment of 
SVD remains suboptimal and the use of functional 
assessment defers PCI in the majority of patients 
[25]. Only 30% of all SVD stenoses that had been 
alleged to be hemodynamically significant based 
on angiography alone were further confirmed to 
be truly significant [25]. Appropriate selection of 
affected vessels is crucial because of increased 
risk of long-term complications of PCI. Puymirat 
et al. [26] compared FFR-guided PCI with angiog-
raphy-guided strategies in SVD and demonstrated 
a lower rate of target lesion revascularization 
(TLR), nonfatal MI, and major adverse cardio-
vascular events (MACE; 15% vs. 29%, p = 
= 0.002) in patients treated with FFR-guided 
PCI as compared with angio-guided PCI. Proce-
dural costs were also reduced in the FFR-guid-
ed strategy (€3253 ± 102 vs. €4714 ± 37, p < 
< 0.0001) [26]. In the angio-guided group, the num-
ber of vessels treated per patient was significantly 
higher, whereas minimal lumen diameter was sig-
nificantly lower as compared with the FFR-guided 
group [26]. These data suggest that FFR improves 
clinical decision-making and outcome in SVD and 
reduces procedural costs. One of the possible 
drawbacks of this method is the possibility of distal 
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perforation with the functional wire especially in 
small tortuous vessels.  
Recently, a new quantitative flow ratio meth-
od of functional evaluation of coronary arteries 
was introduced, which is based on wire-free and 
adenosine-independent analysis of coronary angi-
ography [27]. This promising new diagnostic tool 
was demonstrated to be as effective in vessels 
with diameter of 2.3–2.7 mm as in larger arteries 
with diameter 3.0–3.6 mm [28]. Similar technol-
ogy based on non-invasive fractional flow reserve 
derived from computed tomography (FFRCT) has 
been introduced, but no data regarding its ac-
curacy depending on vessel diameter have been 
published [29].
Intravascular imaging
Intravascular ultrasound (IVUS) is mostly rec-
ommended to guide revascularization of left main 
disease or in cases of stent-related complications 
[22]. Evidence on IVUS-guided PCI in SVD is less 
convincing, although one study suggested that it led 
to a reduction of the number and length of implanted 
stents, median stent diameter, and high-pressure bal-
loon use [30]. Of note, the number of ISRs on 2-year 
follow-up and MACE was significantly lower in the 
IVUS-guided than in the angio-guided group [30]. 
The use of IVUS and optimal coherence to-
mography (OCT) is also decisive in the diagnosis 
of unusual causes of ACS, including spontaneous 
coronary dissection, intramural hematoma, coro-
nary embolism and thrombosis, or angiographically 
missed eroded plaque. Some data show that precise 
OCT-based calculation of post-intervention mini-
mal stent area < 3.5 mm2 in patients treated with 
a 2.5 mm everolimus-eluting stent predicts the 
9-month risk of ISR [31]. Nevertheless, the use of 
IVUS and OCT in vessels < 2.25 mm may be chal-
lenging and increases the risk of iatrogenic plaque 
destabilization, coronary dissection, thrombosis, 
and coronary perforation [32].
Options of myocardial revascularization
The final decision about the revascularization 
should depend on the symptomatic presentation. 
The primary goal of PCI of narrow and frequently 
Intervention strategy depending




Acute occlusion or > 90% stenosis or
FFR < 0.80 or iFR < 0.89 or
evidence or ischaemia
< 2.0 mm 2.0–2.5 mm 2.5–3.0 mm > 3.0 mm
DES
Favours DESFavours DEB
• No or minimal disection (type A–B)
• Diameter 2.0–2.5 mm
• Optimal ow after predilatation
• No residual stenosis
• TIMI 3 • Diameter 2.5–3.0 mm
• Flow-limiting dissection (type C-F)
• Presence of residual stenosis
• TIMI £ 2
Figure 3. Classification of coronary arteries and the management of hemodynamically significant lesions depending 
on vessel diameter; SVD — small vessel disease; ACS — acute coronary syndrome; CCS — chronic coronary syn-
drome; FFR — fractional flow reserve; iFR — instantaneous wave-free ratio;  BMT — best medical therapy; POBA 
— plain old balloon angioplasty; DEB — drug-eluting balloon; DES — drug-eluting stent; TIMI — Thrombolysis in 
Myocardial Infarction score.
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peripheral coronary arteries in CCS patients is 
to provide symptomatic relief. This belief was 
endorsed by recently presented results of the 
pivotal ISCHEMIA trial (International Study of 
Comparative Health Effectiveness With Medical 
and Invasive Approaches) [33], which compared an 
invasive strategy with conservative pharmacologi-
cal management of patients with moderate–severe 
ischemia based on non-invasive stress test [33]. 
The study showed that in a median follow-up time 
of 3.3 years, patients treated conservatively had 
similar outcomes to patients managed invasively, 
as reflected by comparable rates of composite 
endpoint of death, MI, resuscitated cardiac arrest, 
hospitalization for unstable angina, or heart failure 
(15.5% vs. 13.3%, p = 0.34) [33]. Nonetheless, the 
invasive group was characterized by significant 
reduction of symptoms, but only if angina was 
present at baseline [33]. This landmark trial pro-
vided sound evidence for a more lenient approach 
to revascularization in CCS, especially in patients 
with peripheral SVD.
In cases of ACS, PCI or coronary artery bypass 
grafting (CABG) should generally be pursued, 
which is addressed in subsequent sections of the 
manuscript. It should be noted, however, that 
some evidence adjudicates in favor of conservative 
management in very specific clinical situations. In 
the EROSION study Jia et al. [34] found that an-
tithrombotic therapy without stenting is a reason-
able clinical option, provided that plaque erosion 
(not rupture) has been confirmed in OCT imaging. 
This was confirmed by reduction of thrombus 
burden or its disappearance on OCT at 1-month 
[34] and 12-month follow-up [35]. It is vital to note 
that nearly 25% of all patients presented with this 
etiology of ACS [34], which may be regarded as 
a rationale for conservative management of pa-
tients with ACS due to eroded plaque in small 
vessels, especially if the PCI is at risk because of 
small vessel diameter. 
Plain old balloon angioplasty
Since the beginning of invasive cardiology, 
PCI has evolved from plain old balloon angioplasty 
(POBA) and bare-metal stents (BMS) to drug-
coated balloons (DCB) and drug-eluting stents 
(DES), which result in better clinical outcomes 
[36]. Although POBA should be regarded as 
a viable option within coronary arteries < 2.0 mm 
(Fig. 3), in which stent implantation is technically 
impossible or could increase the risk of vessel 
rupture, a number of studies have proven that 
stent implantation confers significantly lower 
risk of restenosis as compared with POBA [7, 
18]. According to some reports, balloon-only PCI 
with optimal postprocedural angiographic flow can 
achieve comparable results to BMS implantation 
in small coronary vessels [18].
Technological development has led to the in-
troduction of commonly available 1.5 mm or even 
smaller balloons; however, no prospective data 
on the results of POBA with this kind of device 
are available. Examples of the smallest balloons 
include the 1.5 mm APEX® Dilatation Catheter 
[37], 1.25 Sprinter® Legend RX, 1.5 mm Euphora® 
Semicompliant Dilatation Catheter [38], 1.0 mm 
Ryurei® Dilatation Catheter [39], and 1.25 Sap-
phire® Coronary Dilatation Catheter [40], which 
are dedicated to dilatation of the most stenotic part 
of the lesion. The even smaller 0.85 mm NIC Nano 
balloon was introduced for PCI of chronic total 
occlusion [41]. All the above-mentioned balloon 
catheters share different technical specifications, 
and an overview is beyond the scope the current 
manuscript. Nowadays these dilatation catheters are 
primarily used for stepped lesion preparation prior 
to stenting of larger coronary arteries. Randomized 
controlled trials are warranted to assess the safety 
and feasibility of these devices for POBA in SVD. 
BMS and DES
Stent implantation has become the core ele-
ment of PCI in the majority of procedures, includ-
ing SVD [18]. Accordingly, with the advent of DES 
showing better efficacy in terms of lower rates of 
ISR and TLR, combarable risk of ST and mortality, 
second-generation DES implantation is the state-
of-the-art management of patients with CAD within 
vessels large enough to accommodate a stent [42]. 
Although the ISR rate has generally diminished, 
the efficacy of DES within small coronary arter-
ies is lower [43, 44]. A wall injury induced by 
stent implantation initiates a vasculoproliferative 
cascade with smooth muscle cell proliferation 
and neointimal hyperplasia [45]. This protrusion 
is independent of nominal vessel size, so smaller 
coronary arteries are more prone to late luminal 
loss and are less able to accommodate neointimal 
tissue without blood flow limitation [46, 47]. The 
DUTCH PEERS randomized trial assessed novel 
DES (zotarolimus and everolimus) in patients with 
SVD [5]. The rates of TLF were significantly higher 
in patients with target lesion being < 2.5 mm than 
in those that were ≥ 2.5 mm (8.6% vs. 5.4%, p = 
= 0.01), and acute myocardial infarction (AMI) was 
numerically, but not significantly, higher (2.7% vs. 
1.2%, p = 0.04) [5]. Another study with a sirolimus-
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eluting stent (SES) and angiographic follow-up 
showed higher restenosis rates in patients with 
lesions smaller than 2.41 mm, as compared with 
those over ≥ 2.41 mm [48]. 
The current evidence regarding the use of 
BMS/DES is summarized in Table 1. According 
to the C-SIRUS trial, deployment of SES instead 
of BMS has improved TLR from 52% to only 2% 
[49]. Similar results were confirmed in other trials 
with a very low late loss ranging between 0.05 and 
0.20 mm [21, 48, 49]. Moreover, the median TLR 
rate was 7% for SES in comparison to 15% and 
13% for a paclitaxel-eluting stent (PES) and DCB, 
respectively [50]. SES significantly reduced the 
odds of TLR compared to PES (odds ratio [OR] 
0.39), DCB (OR 0.34) and BMS (OR 0.21), but there 
were no differences in the rate of AMIs among 
patients [50]. 
Factors such as lesion length, strut thickness, 
and minimum stent lumen diameter were identified 
as independent predictors of restenosis in DES [45, 
51, 52]. The most powerful predictor of angiographic 
restenosis is the diameter of the vessel, with a 60% 
higher risk of restenosis for each decrease by 0.50 
mm [53]. The TAXUS ATLAS study compared the 
performance of the thin strut (0.095 mm) Taxus 
Liberte 2.25 mm stent and the Taxus Express (0.132 
mm) in small vessels [54]. Thinner stent struts 
significantly reduced the rate of 9-month restenosis 
(18.5% vs. 32.7%, p = 0.02) [54].
Technological development led to the intro-
duction of 2.0 mm stents in order to accommodate 
Table 1. Overview of available evidence concerning percutaneous coronary interventions of small 
coronary vessels.




Intervention Target lesion  
revascularization 
BMS vs. POBA
LASMAL I [76] RCT 246 2.0–2.9 BMS vs. POBA 0.8% vs. 6.6%, p = 0.018
DES vs. BMS
C-SIRIUS [49] RCT 100 2.5–3.0 SES vs. BMS 4% vs. 18%, p = 0.05
SES-SMART [21] RCT 257 ≤ 2.75 SES vs. BMS 9.8% vs. 53.1%, p < 0.001
E-SIRIUS [77] RCT 352 2.5–3.0 SES vs. BMS 4% vs. 20.9%, p < 0.0001
DES vs. DES
ISAR-SMART 3 [78] RCT 360 < 2.8 PES vs. SES 14.7% vs. 6.6%, p = 0.008
DCB vs. POBA/BMS/DES
PICCOLETO [79] RCT 57 ≤ 2.75 DCB vs. PES 10.3%, vs. 32.1%, p = 0.043
BELLO [63] RCT 182 < 2.8 DCB vs. PES 4.4% vs. 7.6%, p = 0.37
BASKET-SMALL 2 [19] RCT 758 < 3.0 DCB vs. DES 3.4% vs. 4.5%, p = 0.4375
Giannini et al. [64] Cohort 
study
181 < 2.8 DCB vs. EES 4.4% vs. 5.6%, p = 0.720
Sim et al. [80] Cohort 
study
87 2.0 DCB vs. DES 7.0% vs. 8.2%, p = 0.73
Nishiyama et al. [81] RCT 60 < 3.0 DCB vs. DES 0.0% vs. 6.1%, p = 0.169
Funatsu et al. [82] RCT 135 < 2.8 DCB vs. POBA 2.3% vs. 10.3%, p = 0.07
Her et al. [83] Case-con-
trol study
72 2.5–3.0 DCB vs. POBA 0% vs. 13%, p = 0.033
Sinaga et al. [65] Case-con-
trol study
335 ≤ 2.5 DCB vs. DES 5.2% vs. 3.7%, p = 0.601
Shin et al. [84] Cohort 
study
66 < 3.0 DCB vs. DES/BMS 0% vs 5%, p = NS
RESTORE SVD [66] RCT 256 2.0–2.75 DCB vs. ZES 2 years: 5.2% vs. 2.8%, p = 0.5
SCAAR Report [67] Cohort 
study
14,788 ≤ 2.5 DCB vs. DES 4.1% vs. 1.8%, p < 0.001
DCB — drug-coated balloon; DES — drug-eluting stent; POBA — plain old balloon angioplasty; RCT — randomized controlled trial; 
BMS — bare metal stent; EES — everolimus-eluting stent; PES — paclitaxel-eluting stent; SES — sirolimus-eluting stent;  
ZES — zotarolimus-eluting stent
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for smaller vessel size, but the clinical benefit of 
small stent implantation (≤ 2.25 mm) is vague [55]. 
The new portfolio of 2.0 mm DES (everolimus-
-eluting Xience Xpedition SV or Xience Alpine; 
zotarolimus-eluting Resolute Onyx) created new 
options of PCI in a smaller vascular territory, with 
promising results in retrospective analysis [55, 56]. 
Drug-coated balloons
Drug-coated balloon therapy (otherwise 
known as drug-eluting balloon, DEB) has been 
proposed as an alternative to DES in SVD, obvi-
ating the need for implantation of a foreign body 
into a small artery [57]. The technique is based 
on rapid delivery of an antiproliferative drug to 
the arterial wall from a semi-compliant balloon 
covered with a lipophilic matrix [58]. Therapeutic 
agents, most commonly paclitaxel, are delivered 
during single balloon inflation, which should last 
between 30 and 60 seconds depending on the DCB 
type [58]. A crucial step prior to deployment of 
DCB consists of adequate lesion preparation with 
a successful predilatation to avoid elastic recoil 
and flow-limiting dissections [59]. It was shown 
to provide a good initial angiographic result [59]. 
The basic principles of PCI with the use of DCB 
are highlighted in Table 2 [60]. 
In the past, DCB was primarily utilized for the 
treatment of ISR, which constitutes its primary in-
dication with class IA recommendation in line with 
current European Society of Cardiology Guidelines 
on Myocardial Revascularization [22, 61]. How-
ever, numerous recent studies have focused on 
the possible application of DCB for the treatment 
of de-novo lesions within small coronary arteries. 
A few randomized controlled trials compared the 
efficacy of DCB and DES in SVD. A summary of 
available evidence concerning the comparison of 
DCB and DES in SVD is presented in Table 1 [62]. 
The results of the BELLO study are worth 
mentioning, which compared the IN.PACT Falcon 
paclitaxel-coated balloon with PES Taxus Liberte 
in vessels with a mean diameter of 2.15 mm [63]. 
The study showed promising lower late lumen in 
the DCB group than in the PES group (0.08 mm 
vs. 0.29 mm, p < 0.001), but similar event rates 
were reported in both groups [63]. This was con-
firmed in propensity score analysis of the BELLO 
population [64].
More recently Sinaga et al. [65] performed 
a retrospective analysis of 335 patients treated ei-
ther with DCB or DES by means of device ≤ 2.5 mm. 
This real-world analysis showed that although the 
DCB group had lower acute lumen gain than DES 
group, the 1-year MACE rate (11.6% vs. 11.7%, 
p =1.0) and TLR (5.2% vs. 3.7%, p = 0.601) were 
comparable between both cohorts [65]. 
Similar efficacy between DCB and DCB within 
relatively small coronary vessels was further cor-
roborated by the high-volume BASKET-SMALL 2 
study [19]. This open-label randomized trial com-
prised 758 patients with native lesions in vessels 
< 3.0 mm to either DCB or second-generation DES 
implantation [19]. The use of DCB was non-inferior 
Table 2. Principles of percutaneous coronary intervention with drug-coated balloons (DCB) [60, 62].
1. The lesion should be prepared prior to the use of DCB. DCB should serve only as a vector of antiproliferative 
drug.
2. Predilatation with semi-compliant balloon sized 0.8–1.0 to reference vessel diameter with higher than  
nominal pressure.
3. Use of non-compliant balloons or scoring/cutting balloons or rotablation in the case of complex lesions.
4. Prior to using DCB, check the deliverability of DCB to peripheral lesions. Severe proximal calcifications can 
prevent the transfer of DCB to the culprit lesion.
5. DCB should not be applied in lesions with residual stenosis > 30% or with type C–F dissection following  
initial predilatation. Consider DES implantation.
6. DCB should not be exposed to or immersed into the saline as the drug can be released in the solvent,  
not the culprit lesion.
7. DCB should be swiftly deployed in the lesion, as the drug can be dissolved in the catheter or in non-culprit 
segment of the artery.
8. DCB should be sized 0.8–1.0 to reference vessel diameter and inflated for at least 30–60 s depending on the 
DCB type.
9. Angiographic or intravascular assessment of possible complications (dissection).
10. Dual antiplatelet therapy for as little as 1 month in patients with chronic coronary syndrome.
www.cardiologyjournal.org 773
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to second-generation DES in terms of MACE oc-
currence (cardiovascular death, non-fatal AMI, 
target vessel revascularization) at 12 months (7.5% 
vs. 7.3%, hazard ratio [HR] 0.97, p = 0.918) [19].
Also, the RESTORE SVD randomized trial 
compared DCB with zotarolimus-eluting stent in 
256 patients with de novo lesions within vessels 
between 2.0 and 2.75 mm in size [66]. TLF did not 
differ significantly between DCB and DES group at 
2 years (5.2% vs. 3.7%, p = 0.75) [66].
In contrast to former reports, doubt was cast 
on the efficacy of DCB in de novo SVD in the recent 
SCAAR report [67]. This retrospective registry-
-based Swedish study comprised 14,788 patients 
treated with either DCB or second-generation DES 
for stenoses in arteries ≤ 2.5 mm [67]. The propen-
sity score-matched analysis denoted that the DCB 
group was characterized by significantly higher risk 
of restenosis at 3 years (HR 2.027, 95% confidence 
interval [CI] 1.537–2.674) but had comparable risk 
of lesion thrombosis, AMI, and all-cause death 
to the DES group [67]. Despite its retrospective 
design, the present study is the largest report 
concerning SVD treatment with DCB. Further 
high-volume prospective studies are required to 
verify the conflicting results of the trials.
In spite of divergent data on risk of restenosis 
[19, 67], DCB represents a viable interventional 
option in patients with native SVD, with similar 
risk of adverse events and mortality to contempo-
rary DES technology. The advantages of DCB over 
stent implantation include significantly lower risk 
of acute thrombosis, potentially favorable vascular 
remodeling after PCI, and dual antiplatelet therapy 
shortened to 4 weeks in stable patients, which may 
reduce the risk of major bleeding and bring addi-
tional clinical benefit [19]. DCB should be applied 
particularly within in-stent restenosis, in de novo 
lesions ranging from 2.0 mm to 2.5 mm, and as an 
adjunct to DES implantation for side branch PCI 
in selected cases (Fig. 3) [68].
Bioresorbable scaffolds
Bioresorbable scaffolds (BRS) were designed 
to allow for gradual resorption of stent components, 
which seemed to be attractive in the context of pos-
sible PCI in SVD [69]. This approach was thought 
to provide similar benefits as DES, at same time 
being minimally invasive. Conversely, the first-
generation lactic acid BRS was shown to confer 
greater risk of subacute, late, and very late stent 
thrombosis and a higher rate of TLR, most likely 
due to the design of thick lactic acid struts [70, 71]. 
This led to contraindication for these devices to be 
used in routine clinical practice outside of clinical 
trials and recommendation for prolonged dual an-
tiplatelet therapy > 12 months [21]. The potential 
benefit of these stents in SVD was outweighed by 
even greater risk of poor outcome within small 
coronary vessels [72]. The retrospective analysis 
by Wiebe et al. [72] provided evidence that implan-
tation of the smallest 2.5 mm BRS was linked to 
higher risk of TLF (HR 1.31, 95% CI 1.01–1.69). 
There are numerous ongoing trials evaluating the 
application of experimental bioresorbable technolo-
gies, including magnesium-based bioresorbable 
stents [73]. Time will show if these solutions are 
safe in the clinical setting of SVD.
CABG
Coronary artery bypass grafting represents 
a cornerstone of myocardial revascularization in 
patients with multivessel CAD and high SYNTAX 
score [74]. Multivessel CAD is frequently accompa-
nied by the presence of SVD. Based on convincing 
evidence from high-volume reports, CABG is not 
a preferable choice of treatment in SVD due to an 
increased risk of technical failure and risk of MACE 
[75]. O’Connor et al. [75] studied the impact of 
gender, body size, and mid-left anterior descend-
ing artery dimeter on the in-hospital mortality of 
patients submitted to CABG [76]. The in-hospital 
mortality amounted to 15.8% in patients with 
a diseased vessel diameter of 1.0 mm, while it was 
as low as 1.5% in patients with a grafted vessel 
size of 2.5–3.5 mm [75]. This constitutes a strong 
indicator that vessel size should be regarded as one 
of the core variables in the decision-making process 
during Heart Team meetings. Unfortunately, the 
reference tool for evaluation of morphology and 
degree of CAD, namely the SYNTAX score, does 
not account for vessels < 1.5 mm and it does adjust 
risk score to vessel diameter in larger arteries, 
which represents a major limitation of the current 
approach [74].
Conclusions
Small vessel disease is a challenging condi-
tion due to its equivocal definition and abundance 
of different therapeutic options. Revascularization 
should be performed in patients with confirmed 
ischemia and only in cases of hemodynamically 
significant lesions based on functional assessment, 
which has proven even more important in small 
vessel diameter. The diameter of the diseased ves-
sel represents the most potent variable affecting 
long-term outcome after PCI in SVD. The choice 
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between DES or DCB should be based on a number 
of clinical variables, including vessel size, ischemic 
territory, and lesion characteristics. In the group 
of lesions > 2.5 mm, the application of DES is 
associated with a more favorable clinical outcome 
with low rate of TLR, while both DCB and DES 
tend to show similar efficacy in the vessel diameter 
between 2.0 and 2.5 mm. In this clinical setting, 
DCB is an alternative to DES, with the advantage 
of positive vascular remodeling and shortened dual 
antiplatelet therapy. Very small coronary vessels 
< 2.0 mm should either be treated with POBA 
or best medical therapy, especially in the case of 
chronic coronary syndromes. SVD remains an un-
explored clinical setting, which requires extensive 
research into the indications and optimal methods 
of myocardial revascularization.
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